Only two of fourteen HNSCC cell lines did not respond to Erlotinib and these may be driven by other oncogenes as KYSE-70 has an PIK3CA amplification [21] and KYSE-510 bears c-myc, hst-1 and cyclin D1 amplifications [22]. Here, MYC is linked to head and neck squamous cell carcinoma.